Journal of Hematology & Thromboembolic Diseases
Open Access

Yukio Hirabayashi

Publications

• Case Report
  An Aggressive Transformation to EBV-Positive Hodgkin Lymphoma after Bendamustine-Containing Chemotherapy for Marginal Zone Lymphoma
  Author(s): Nakazawa H, Sakai H, Kawakami T, Hirabayashi Y, Nakazawa K, et al. Nakazawa H, Sakai H, Kawakami T, Hirabayashi Y, Nakazawa K, et al.
  
  EBV-positivelymphoproliferative disorders are well documented phenomenon after fludarabine therapy. Although bendamustine shares common chemical structure with fludarabine, therapy-related malignancies have rarely been reported. A seventy-three-year-old man was presented with splenomegaly and pharyngeal mass. The biopsies of bone marrow and the mucosal mass revealed he had splenic marginal zone lymphoma, stage IV. Six months later, he received one course of R-CHOP and splenectomy. Three months after the surgery, the lymphoma progressed with massive pleural effusion, and six courses of bendamustine plus rituximab, yielding minimal response of the disease. Six months after the completion of bendamustine, however, Pel-Ebstein-like fever and progression of lymphadenopathy ensued. A lymph node biopsy exhibited he had EBV-positive classical Hodgkin lymphoma concomitant with marginal zone lymph.. View More»
  DOI: 10.4172/2329-8790.1000246

  Abstract PDF

Relevant Topics